← Pipeline
Registered human trialNot yet recruitingNo efficacy data yet
Phase 1/2
ReINFORCE
Clemastine • acute demyelinating lesions
Practical availability: Research record — not presented as established care
- Compound / intervention
- Clemastine • acute demyelinating lesions
- Mechanism
- Clemastine; muscarinic-receptor antagonism
- Development stage
- Phase 1/2
- Status
- Not yet recruiting • scheduled start 15 Sep 2026
- Population / locations
- Site: UCSF, US • not yet recruiting
- Evidence level
- Human Phase 1/2 • no results
Next substantive checkpoint
Recruitment opening and multiparametric MRI readouts for myelin repair
Related substantive developments
No separate substantive update is currently linked.